Islam Badar Ul, Zaidi Syed Kashif, Kamal Mohammad Amjad, Tabrez Shams
Department of Biochemistry, J. N. Medical College, Faculty of Medicine, Aligarh Muslim University, Aligarh 202002. India.
Center of Excellence in Genomic Medicine Research, King Abdulaziz University, Jeddah 21589. Saudi Arabia.
Curr Drug Metab. 2017;18(9):808-813. doi: 10.2174/1389200218666170203110135.
Alzheimer's disease (AD) is an irreversible multifaceted neurodegenerative disorder that gradually degrades neuronal cells. It is the most frequent cause of memory loss and dementia in elderly individuals worldwide. The extracellular deposition of beta amyloid (Aβ), intracellular neurofibrillary tangles (NFTs) retention, neuronal decline and neurotransmitter system derangement are the patho-physiological marker of this devastated disease Objective: In view of limited treatment option and their success rate, there is an urgent need to explore the vast array of proteomes for the management of AD. These proteins could be therapeutically targeted to prevent the progression of this disease. In the present review, we tried to uncover several proteins that could be exploited in AD therapeutics.
Based on our article, we conclude that proteome based AD treatment needs more refinements and approaches to achieve the desired success rate.
阿尔茨海默病（AD）是一种不可逆的多方面神经退行性疾病，会逐渐使神经元细胞退化。它是全球老年人记忆力丧失和痴呆症最常见的病因。β淀粉样蛋白（Aβ）的细胞外沉积、细胞内神经原纤维缠结（NFTs）的留存、神经元衰退和神经递质系统紊乱是这种毁灭性疾病的病理生理标志物。目的：鉴于治疗选择有限及其成功率，迫切需要探索大量蛋白质组来管理AD。这些蛋白质可作为治疗靶点以阻止该疾病的进展。在本综述中，我们试图揭示几种可用于AD治疗的蛋白质。
基于我们的文章，我们得出结论，基于蛋白质组的AD治疗需要更多的改进和方法来达到预期的成功率。
